Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Jazz Pharmaceuticals plc Director's Dealing 2016

May 26, 2016

30751_dirs_2016-05-26_c365bd16-b03b-4d41-b586-57d34c35ef85.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2016-05-24

Reporting Person: Mulligan Seamus (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-05-24 Ordinary Shares S 1400.0 $148.6464 Disposed 1101179 Direct
2016-05-24 Ordinary Shares S 11888.0 $149.6377 Disposed 1089291 Direct
2016-05-24 Ordinary Shares S 9954.0 $150.7238 Disposed 1079337 Direct
2016-05-24 Ordinary Shares S 4726.0 $151.51 Disposed 1074611 Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.18 to $149.14. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $149.18 to $150.17. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $150.18 to $151.17. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $151.18 to $151.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.